What’s Going on with Gene Therapy?

Recent Gene Therapy News
On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas (ALPMY) for over $3 billion, announced that a third patient has passed away in a clinical trial evaluating its gene therapy product AT132 for the treatment of the life-threatening neuromuscular X-linked Myotubular Myopathy (XLMTM).

The neuromuscular disease is . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.